vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and REGAL REXNORD CORP (RRX). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.5B, roughly 1.1× REGAL REXNORD CORP). Edwards Lifesciences runs the higher net margin — 23.1% vs 4.3%, a 18.7% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 4.3%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -2.2%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

Regal Rexnord Corporation is a manufacturer of electric motors and power transmission components based in Milwaukee, Wisconsin. The company has manufacturing, sales, and service facilities throughout the United States, Canada, Mexico, Europe, and Asia, with about 29,000 employees.

EW vs RRX — Head-to-Head

Bigger by revenue
EW
EW
1.1× larger
EW
$1.6B
$1.5B
RRX
Growing faster (revenue YoY)
EW
EW
+12.4% gap
EW
16.7%
4.3%
RRX
Higher net margin
EW
EW
18.7% more per $
EW
23.1%
4.3%
RRX
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
-2.2%
RRX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
EW
EW
RRX
RRX
Revenue
$1.6B
$1.5B
Net Profit
$380.7M
$64.3M
Gross Margin
78.0%
37.2%
Operating Margin
1.8%
10.3%
Net Margin
23.1%
4.3%
Revenue YoY
16.7%
4.3%
Net Profit YoY
6.8%
12.2%
EPS (diluted)
$0.66
$0.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
RRX
RRX
Q1 26
$1.6B
$1.5B
Q4 25
$1.6B
$1.5B
Q3 25
$1.6B
$1.5B
Q2 25
$1.5B
$1.5B
Q1 25
$1.4B
$1.4B
Q4 24
$1.4B
$1.5B
Q3 24
$1.4B
$1.5B
Q2 24
$1.4B
$1.5B
Net Profit
EW
EW
RRX
RRX
Q1 26
$380.7M
$64.3M
Q4 25
$91.2M
$63.4M
Q3 25
$291.1M
$79.6M
Q2 25
$333.2M
$79.2M
Q1 25
$358.0M
$57.3M
Q4 24
$385.6M
$41.2M
Q3 24
$3.1B
$72.7M
Q2 24
$366.3M
$62.5M
Gross Margin
EW
EW
RRX
RRX
Q1 26
78.0%
37.2%
Q4 25
78.1%
37.5%
Q3 25
77.8%
37.0%
Q2 25
77.5%
37.7%
Q1 25
78.7%
37.2%
Q4 24
78.9%
34.9%
Q3 24
80.6%
37.7%
Q2 24
79.9%
36.9%
Operating Margin
EW
EW
RRX
RRX
Q1 26
1.8%
10.3%
Q4 25
9.6%
10.8%
Q3 25
19.8%
11.6%
Q2 25
26.8%
12.2%
Q1 25
27.9%
11.3%
Q4 24
22.6%
8.8%
Q3 24
25.9%
11.8%
Q2 24
26.8%
12.5%
Net Margin
EW
EW
RRX
RRX
Q1 26
23.1%
4.3%
Q4 25
5.8%
4.2%
Q3 25
18.7%
5.3%
Q2 25
21.7%
5.3%
Q1 25
25.3%
4.0%
Q4 24
27.8%
2.8%
Q3 24
226.7%
4.9%
Q2 24
26.7%
4.0%
EPS (diluted)
EW
EW
RRX
RRX
Q1 26
$0.66
$0.96
Q4 25
$0.16
$0.95
Q3 25
$0.50
$1.20
Q2 25
$0.56
$1.19
Q1 25
$0.61
$0.86
Q4 24
$0.65
$0.61
Q3 24
$5.13
$1.09
Q2 24
$0.61
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
RRX
RRX
Cash + ST InvestmentsLiquidity on hand
$401.0M
Total DebtLower is stronger
$4.7B
Stockholders' EquityBook value
$6.8B
Total Assets
$13.8B
Debt / EquityLower = less leverage
0.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
RRX
RRX
Q1 26
$401.0M
Q4 25
$4.2B
$521.7M
Q3 25
$3.8B
$400.0M
Q2 25
$4.1B
$320.1M
Q1 25
$3.9B
$305.3M
Q4 24
$4.0B
$393.5M
Q3 24
$4.4B
$458.6M
Q2 24
$2.0B
$510.4M
Total Debt
EW
EW
RRX
RRX
Q1 26
$4.7B
Q4 25
$4.8B
Q3 25
Q2 25
Q1 25
Q4 24
$5.5B
Q3 24
$5.7B
Q2 24
$5.8B
Stockholders' Equity
EW
EW
RRX
RRX
Q1 26
$6.8B
Q4 25
$10.3B
$6.8B
Q3 25
$10.2B
$6.8B
Q2 25
$10.5B
$6.7B
Q1 25
$10.1B
$6.4B
Q4 24
$10.0B
$6.3B
Q3 24
$9.5B
$6.5B
Q2 24
$7.4B
$6.4B
Total Assets
EW
EW
RRX
RRX
Q1 26
$13.8B
Q4 25
$13.7B
$13.9B
Q3 25
$13.3B
$13.9B
Q2 25
$13.5B
$13.9B
Q1 25
$13.0B
$14.0B
Q4 24
$13.1B
$14.0B
Q3 24
$13.0B
$14.6B
Q2 24
$10.1B
$14.6B
Debt / Equity
EW
EW
RRX
RRX
Q1 26
0.69×
Q4 25
0.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.88×
Q3 24
0.87×
Q2 24
0.91×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
RRX
RRX
Operating Cash FlowLast quarter
$14.9M
Free Cash FlowOCF − Capex
$-2.5M
FCF MarginFCF / Revenue
-0.2%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.23×
TTM Free Cash FlowTrailing 4 quarters
$805.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
RRX
RRX
Q1 26
$14.9M
Q4 25
$450.9M
$167.8M
Q3 25
$573.7M
$197.5M
Q2 25
$290.2M
$523.2M
Q1 25
$280.4M
$102.3M
Q4 24
$-127.5M
$213.2M
Q3 24
$351.8M
$154.8M
Q2 24
$371.5M
$158.3M
Free Cash Flow
EW
EW
RRX
RRX
Q1 26
$-2.5M
Q4 25
$353.5M
$140.6M
Q3 25
$516.2M
$174.0M
Q2 25
$240.9M
$493.0M
Q1 25
$224.4M
$85.5M
Q4 24
$-177.3M
$183.9M
Q3 24
$299.9M
$125.5M
Q2 24
$286.1M
$125.9M
FCF Margin
EW
EW
RRX
RRX
Q1 26
-0.2%
Q4 25
22.5%
9.2%
Q3 25
33.2%
11.6%
Q2 25
15.7%
33.0%
Q1 25
15.9%
6.0%
Q4 24
-12.8%
12.6%
Q3 24
22.1%
8.5%
Q2 24
20.9%
8.1%
Capex Intensity
EW
EW
RRX
RRX
Q1 26
Q4 25
6.2%
1.8%
Q3 25
3.7%
1.6%
Q2 25
3.2%
2.0%
Q1 25
4.0%
1.2%
Q4 24
3.6%
2.0%
Q3 24
3.8%
2.0%
Q2 24
6.2%
2.1%
Cash Conversion
EW
EW
RRX
RRX
Q1 26
0.23×
Q4 25
4.94×
2.65×
Q3 25
1.97×
2.48×
Q2 25
0.87×
6.61×
Q1 25
0.78×
1.79×
Q4 24
-0.33×
5.17×
Q3 24
0.11×
2.13×
Q2 24
1.01×
2.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons